Remifentanil is a strong pain reliever and sedative used during surgery and other medical procedures to keep patients comfortable and help them stay calm while under anesthesia.[2] Ultiva is currently approved and in use across 51 indications[4].[1]
Ultiva is one of 676 small molecule programs targeting Stroke. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
268 competitors in Colorectal Cancer
Camptosar
Beyfortus
Adrucil
Wellcovorin
Ultiva
Bayer Aspirin
Acetylsalicylic Acid
TAS 102
Systemic Chemotherapy
BL-M07D1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jul 12, 1996
ULTIVA
NDA NDA020630
Sources
Details